Novel Anti-RSV Dianionic Dendrimer-Like Compounds: Design, Synthesis and Biological Evaluation

Author(s): Anna Gazumyan, Boris Mitsner, George A. Ellestad.

Journal Name: Current Pharmaceutical Design

Volume 6 , Issue 5 , 2000

Become EABM
Become Reviewer

Abstract:

Human Respiratory Syncytial Virus (RSV) is considered to be the leading cause of lower respiratory tract disease in infants and young children. RSV is also a common pathogen in immunocompromised adults and in the elderly. RSV infection can be epidemic and is evident worldwide. Ribavirin, a small molecule agent, and Synagis TM , a monoclonal neutralizing antibody, are the only approved drugs for treatment and prevention of RSV in high-risk patients. This review is focused on a group of novel and specific inhibitors discovered at Wyeth-Ayerst Research. Some of these inhibitors have IC 50 less than 50 nM and are active against all the tested group A and B viruses. They also have shown good efficacy in cotton rats and primates. Mechanism of action studies indicate that the compounds inhibit the next step in infection after adsorption suggesting that fusion is the target. A strong relationship between the inhibitor structures and their anti-RSV activity was established. This relationship appears to derive from a multivalent interaction between the functional groupings of the inhibitors and the F protein, which seem to be highly complementary and directional.

Keywords: Anit RSV Dianionic Dendrimer like compounds design synthesis, biological Evaluation, human Respiratory Syncytial Virus RSV, Ribavirin, Synagis TM a monoclonal neutralizing antibody, Epidemiology infection, fusion, hydrophobic glycoprotein, treatment, chemotherapy, Inhibitors RNA Transcription, antisense oligonucleotides, Polyoxometalates, modified, sulfonamides

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 6
ISSUE: 5
Year: 2000
Page: [525 - 546]
Pages: 22
DOI: 10.2174/1381612003400704
Price: $58